Cart
sales@molnova.com
Troxipide
CAS No. 30751-05-4
Troxipide( BRN0493078 | Troxipide | Troxipida | Troxipidum )
Catalog No. M13981 CAS No. 30751-05-4
Troxipide is a novel systemic non-antisecretory gastric cytoprotective agent with anti-ulcer, anti-inflammatory and mucus secreting properties irrespective of pH of stomach or duodenum.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | 45 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTroxipide
-
NoteResearch use only, not for human use.
-
Brief DescriptionTroxipide is a novel systemic non-antisecretory gastric cytoprotective agent with anti-ulcer, anti-inflammatory and mucus secreting properties irrespective of pH of stomach or duodenum.
-
DescriptionTroxipide is a novel systemic non-antisecretory gastric cytoprotective agent with anti-ulcer, anti-inflammatory and mucus secreting properties irrespective of pH of stomach or duodenum.(In Vitro):Troxipide exerts inhibitory, therapeutic and preventive effects to specifically those in the stomach by enhancing gastric mucosal blood flow and gastric mucosal defense factors and promoting tissue repair, blood circulation, metabolism and GU repair.(In Vivo):Troxipide (40 mg/kg; iv) significantly alleviates gastric ulcer (GU).Troxipide (40 mg/kg; iv) has a T1/2 of 210 min and 428.73 min for NCG and GUG rat, respectively.
-
In VitroTroxipide exerts inhibitory, therapeutic and preventive effects to specifically those in the stomach by enhancing gastric mucosal blood flow and gastric mucosal defense factors and promoting tissue repair, blood circulation, metabolism and GU repair.
-
In VivoTroxipide (40 mg/kg; iv) significantly alleviates gastric ulcer (GU). Troxipide (40 mg/kg; iv) has a T1/2 of 210 min and 428.73 min for NCG and GUG rat, respectively. Animal Model:Normal control group (NCG) and gastric ulcer group (GUG) rat (5% acetic acid 10 mL/kg/day) Dosage:10, 20, 40, 60 mg/kg Administration:Oral; daily; 2 weeks Result:The levels of these cytokines (IL-17, IL-6, TNF-α, IFN-γ and AP-1) were significantly reduced, suggesting that GU was significantly alleviated.Animal Model:NCG and GUG rat Dosage:40 mg/kg for iv Administration:IV Result:Had a T1/2 of 210 min and 428.73 min for NCG and GUG rat, respectively.
-
SynonymsBRN0493078 | Troxipide | Troxipida | Troxipidum
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research AreaInflammation/Immunology
-
Indication——
Chemical Information
-
CAS Number30751-05-4
-
Formula Weight294.35
-
Molecular FormulaC15H22N2O4
-
Purity>98% (HPLC)
-
SolubilityEthanol: 3 mg/mL (10.19 mM); DMSO: 18 mg/mL (61.15 mM)
-
SMILESO=C(NC1CNCCC1)C2=CC(OC)=C(OC)C(OC)=C2
-
Chemical Name3,4,5-trimethoxy-N-(piperidin-3-yl)benzamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Kusugami K, et al. Dig Liver Dis, 2000, 32(4), 305-31
molnova catalog
related products
-
Flavanone
Used as organic synthesis and medicine intermediate.
-
3-Chloro-L-Tyrosine
3-Chlorotyrosine a specific marker of myeloperoxidase-catalyzed oxidation is markedly elevated in low-density lipoprotein isolated from human atherosclerotic intima. In particular myeloperoxidase halogenates tyrosine residues in plasma proteins and generates 3-chlorotyrosine (CY).
-
Tyroserleutide TFA
Tyroserleutide TFA, isolated from the degradation products of porcine spleen, is a small molecular tripeptide which inhibits tumor growth both in vitro and in vivo.
